Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer (RESToRE)
Endometrium Cancer
About this trial
This is an interventional screening trial for Endometrium Cancer focused on measuring Screening, Prevention, Progesterone Challenge Test, Women's Health, Reproductive health, Menopause
Eligibility Criteria
Inclusion Criteria: Individuals are postmenopausal (must be three (3) years past last menstrual period) Individuals have an intact uterus (have not had a hysterectomy) Exclusion Criteria: Individuals taking hormone therapy for menopause (including vaginal estrogen) Individuals taking male hormones, Individuals on anti-endocrine therapy (such as tamoxifen) Individuals on aromatase inhibitor therapy Individuals who have experienced abnormal uterine bleeding Individuals who have an Intrauterine Device (IUD)
Sites / Locations
- VGH Research PavilionRecruiting
Arms of the Study
Arm 1
Experimental
Progesterone Challenge Test
10-day course of medroxyprogesterone acetate (Provera) 10 mg per os (po) daily.